Boston Scientific overturns $42m patent verdict on appeal

Years of litigation over biodegradable drug-delivery technology took another turn after the Federal Circuit delivered a significant win for the medical device maker.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

MedTech

Invisalign maker secures first China win against clear aligner rival

13 August 2026 Clear aligner rivals are fighting over orthodontic technology across several major markets and the latest development in China has raised the stakes.

MedTech

The UPC plugs another gap in its procedural rulebook

7 August 2026 A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.

MedTech

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

3 August 2026 The medical device maker says that a split appellate decision raises broader questions about trade secret law, jurisdiction and when the clock starts ticking on misappropriation claims.

More features

Former USPTO acting director takes the helm at C4IP

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Novartis scores UK win in high-stakes Entresto fight

Invisalign maker secures first China win against clear aligner rival

Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Exclusive: ‘In the end, I did it my own way’ and became a UPC judge

Lilly mounts defence as generics circle Mounjaro and Zepbound

Boston Scientific overturns $42m patent verdict on appeal

More on this story

Editor's picks

Editor's picks

More features